OR9G9 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Diphenhydramine hydrochloride | 147-24-0 | sc-204729 sc-204729A sc-204729B | 10 g 25 g 100 g | $51.00 $82.00 $122.00 | 4 | |
Diphenhydramine, an antihistamine, can inhibit histamine receptors, which may participate in signaling pathways essential for OR9G9 activity. By blocking these receptors, diphenhydramine can disrupt the downstream signaling that is necessary for the functional activity of OR9G9. | ||||||
Quinine | 130-95-0 | sc-212616 sc-212616A sc-212616B sc-212616C sc-212616D | 1 g 5 g 10 g 25 g 50 g | $77.00 $102.00 $163.00 $347.00 $561.00 | 1 | |
Quinine is known to inhibit multiple ion channels, including those that may regulate the activity of OR9G9. By altering ion flux, quinine can inhibit the signaling cascades that are essential for the proper functioning of OR9G9. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Diltiazem inhibits calcium channels, which can lead to a decrease in intracellular calcium levels. Since calcium signaling is vital for a multitude of cellular processes, this inhibition can disrupt pathways that OR9G9 is involved in, thereby inhibiting its function. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
Losartan, an angiotensin receptor blocker, can inhibit the angiotensin II receptor which is involved in signaling pathways that could regulate the function of OR9G9. By blocking this receptor, losartan can impede the signaling required for the activity of OR9G9. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil is a calcium channel blocker that can inhibit the influx of calcium ions. As calcium ions play a pivotal role in signaling pathways, particularly in G-protein-coupled receptor (GPCR) functions, the inhibition by verapamil can result in the functional inhibition of OR9G9. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Amiloride can inhibit sodium channels and certain transporters, which can disrupt sodium homeostasis. This disturbance can inhibit the sodium-dependent signaling pathways that OR9G9 might rely on, leading to its inhibition. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $66.00 | 4 | |
Omeprazole, a proton pump inhibitor, can disrupt the pH balance within cellular compartments. Since pH is crucial for the conformation and function of many proteins, the inhibition of proton pumps by omeprazole can lead to the functional inhibition of OR9G9 by altering its optimal pH environment. | ||||||
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $50.00 $128.00 | ||
Lidocaine is a sodium channel blocker that can inhibit action potentials and signaling within neurons. If OR9G9 is involved in neuronal signaling, the inhibition of sodium channels by lidocaine could result in the functional inhibition of OR9G9 by preventing proper signal transduction. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine is another calcium channel blocker that can inhibit the influx of calcium ions into cells. This inhibition can disrupt calcium-dependent signal transduction pathways, which could be essential for the activity of OR9G9, leading to its functional inhibition. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a beta-adrenergic receptor antagonist that can inhibit the sympathetic nervous system's signaling. Since OR9G9 might be involved in adrenergic signaling pathways, the inhibition of these receptors by propranolol can disrupt the activity of OR9G9. | ||||||